Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Is Ibuprofen recalled?

Yes — there is an active recall. 15 ongoing FDA recalls mention Ibuprofen (68 total). Check the affected lots below.

Most common reason: cGMP deviation (21 of these recalls)

Recalls are matched by product description. A recall usually affects specific lots, not every package of Ibuprofen. “Active” means an FDA recall is still ongoing; “closed” means it was terminated or completed. Checked against openFDA on Oct 10, 2026.

Ibuprofen recalls in 2026

1 initiated in 2026, 68 in total — newest first
Class II · Moderate risk

Advil a) Ibuprofen

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0261-2026
Class III · Low risk

IBU (ibuprofen)

Failed Tablet/Capsule Specifications

Ongoing Failed specification Dr. Reddy's Laboratories, Inc. NDC 55111-683-05 D-0047-2025
Class II · Moderate risk

Ibuprofen 800mg

Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.

Ongoing Impurity / degradation Direct Rx NDC 61919-0621-15 D-0041-2025
Class II · Moderate risk

Ibuprofen Tablets

Failed Impurities/Degradation Specifications - at 18-month Stability testing

Ongoing Impurity / degradation Preferred Pharmaceuticals, Inc. NDC 68788-9110-03 D-0647-2024
Class II · Moderate risk

IBU Ibuprofen Tablets

Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-682-01 D-0646-2024
Class II · Moderate risk

IBU Ibuprofen Tablets

Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-683-01 D-0645-2024
Class II · Moderate risk

IBU Ibuprofen Tablets

Failed impurities/degradation specifications: results for unknown impurity, were 0.13% and 0.11% respectively, exceeding the 0.10% specification limit.

Ongoing Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 55111-684-01 D-0644-2024
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0183-2023
Class I · High risk

Advil Liqui Gels

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0182-2023
Class I · High risk

Advil (ibuprofen)

Labeling: Illegible Label; the adhesive migrated onto a portion of the label, causing it to tear when peeled back

Terminated Labeling / mix-up Glaxosmithkline Consumer Healthcare Holdings DBA Haleon D-0181-2023
Class II · Moderate risk

Ibuprofen Oral Suspension USP

Presence of foreign substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

Terminated Particulate / foreign matter Preferred Pharmaceuticals, Inc NDC 68788-7268-01 D-0531-2020